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WORKSHOP/SYMPOSIUM
SUMMARY

Mucopolysaccharidosis Type I Newborn Screening: Best Practices
for Diagnosis and Management
Lorne A. Clarke, MD, CM, FRCPC, FCCMG1, Andrea M. Atherton, MS, CGC2,*, Barbara K. Burton, MD, FAAP, FACMG3,
Debra L. Day-Salvatore, MD, PhD, FAAP, FACMG4, Paige Kaplan, MBBCh, FRCPC, FCCMG, FAAP, FACMG5,
Nancy D. Leslie, MD6, C. Ronald Scott, MD7, David W. Stockton, MD, FACMG8, Janet A. Thomas, MD, FAAP, FACMG9, and
Joseph Muenzer, MD, PhD10

T

he mucopolysaccharidoses (MPS) are a group of rare
progressive genetic disorders of glycosaminoglycan
(GAG) metabolism caused by deficiency of enzymes responsible for lysosomal GAG degradation. The accumulation of partially degraded GAG and the resulting disturbance
of cellular homeostasis leads to progressive cellular and tissue
damage ultimately resulting in multiorgan system involvement.1
Mucopolysaccharidosis type 1 (MPS I) results from deficiency
of the lysosomal enzyme a-L-iduronidase (IDUA) because of
pathogenic variants in the IDUA gene.2 MPS I presents clinically as a disease spectrum spanning early onset, progressive
severe disease with cognitive impairment (Hurler syndrome),
to later onset progressive disease with highly variable and later
onset central nervous system (CNS) involvement (attenuated
MPS I). Attenuated MPS I encompasses a spectrum previously referred to by the eponyms Hurler-Scheie and Scheie
syndromes.1 Untreated patients with the most severe form of
MPS I usually die in the first decade. In contrast, life expectancy for untreated patients with attenuated disease ranges
from mortality in the second or third decade to full life expectancy, albeit with considerable morbidity. The birth incidence of MPS I is ~1 in 100 000 live births estimated from a
number of population studies.3
Although the disease pathophysiology is not well understood, most of the clinical manifestations of MPS I are
secondary deleterious effects because of disturbed GAG metabolism. Organs involved include the brain, musculoskeletal
system, heart, lungs, and eyes. Many symptoms and complications are difficult or impossible to reverse. Thus, initiation
of treatment early in the natural history of disease is thought
to be a key factor in achieving optimal outcome.2 Available
disease modifying therapies include hematopoietic stem cell
transplantation (HSCT) and enzyme replacement therapy
(ERT) with laronidase.4 Because early intervention with HSCT
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has been demonstrated to stabilize neurocognitive function
in MPS I,5-7 it is currently recommended as standard for patients who are predicted to have severe disease.4,6 ERT with
laronidase is used for treating nondirect CNS manifestations
of MPS I. Clinical trials and follow-up studies of ERT in MPS
I have demonstrated improvements in some somatic manifestations and functional outcomes in patients with attenuated MPS I.8-13 Laronidase has also been found to be useful in
the peritransplant period for patients with severe MPS I.4,14 The
use of ERT in the peritransplant period has been shown to be
safe and has led to clinical improvements particularly in patients with significant cardiopulmonary disease before transplantation. In addition, ERT before transplantation has been
reported to alleviate symptoms that may have influenced the
conditioning regime or candidacy for transplantation of some
patients.14
Because MPS I is a progressive disorder, the success of both
HSCT and ERT depends on early initiation of treatment. Therefore, early identification of patients is critical. Because many
of the early disease manifestations represent common childhood symptoms (eg, inguinal/umbilical hernia and recurrent
upper respiratory tract infections), diagnosis based on early
symptom recognition is challenging and has been met with
limited success. Newborn screening (NBS) strategies should
be more effective in this regard. MPS I NBS via determination
of IDUA activity in dried blood spot (DBS)-derived samples
is currently underway in the US15,16 and in pilot programs in
Taiwan,17 Italy,18 Austria,19 and Hungary.19 The US Department
of Health and Human Services recommended uniform screening panel20 provides the list of core and secondary disorders
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Table I. Analysis of symptom frequency in patients ≤2
years of age (from Pastores et al22)
Symptoms/complications
Coarse facies
Valvular disease
Corneal clouding
Hepatomegaly
Upper airway obstruction → OSA
Kyphosis gibbus
Joint contractures
Hernia
Dysostosis multiplex
Cognitive impairment
Enlarged tongue
Splenomegaly
Eustachian tube obstruction → otitis media
Hip dysplasia
Genu valgum
Reactive airway disease
Scoliosis
Carpal tunnel syndrome
Pes cavus
Glaucoma
Heart failure
Cor pulmonale

Percentage of patients ≤2 y
of age with symptom
98
95
90
84
82
75
72
70
70
60
60
60
55
42
38
37
35
25
18
10
3
2

OSA, obstructive Sleep Apnea.

that should be included in every NBS program. A proposal for
MPS I NBS received a positive recommendation by the US Secretary of Health and Human Services’ Advisory Committee
on Heritable Disorders in Newborns and Children,21 and the
US Secretary approved the addition of MPS I to the recommended uniform screening panel in February 2016.

Limited Ability to Define Disease Severity is
an Inherent Challenge for MPS I NBS
Given the wide clinical spectrum of MPS I and the differences in therapy based on subtype, the precise determination
of where a patient fits in the broad spectrum of disease is essential. It is important to note that no currently available biochemical criteria can reliably distinguish phenotypes. Therefore,
additional assessments including molecular analysis and
skilled clinical assessments are required. Table I summarizes
data obtained from the MPS I Registry highlighting the
features observed in patients less than 2 years of age. It is
important to note that many of the signs and symptoms
considered characteristic of MPS I may not necessarily dif-
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ferentiate between attenuated and severe phenotypes, or may
not be present in neonates.23 A summary of the challenges in
predicting MPS I disease severity in individuals detected by
NBS is summarized in Table II.
Lack of Routine Biochemical Markers
The routine laboratory diagnostic IDUA enzyme assay cannot
distinguish between the different phenotypes. Although many
biomarkers of MPS have been reported, their ability to reliably distinguish MPS I subtypes, particularly in early infancy,
has not been demonstrated.24 Patients with Hurler syndrome,
in general, have higher levels of urine GAG (uGAG) than patients with attenuated disease, but the precise threshold
level that distinguishes these subtypes, particularly at early
disease stages, is unknown. In sophisticated studies using
cultured MPS I fibroblasts and evaluating enzyme kinetics,
immunoquantification, and in vitro turnover studies, it was
possible to correlate between the genotype, the biochemical
phenotype, and clinical course.25 This complex assay requires
specific antibodies that make it difficult to reproduce in other
laboratories. The analysis of oligosaccharides, derived from
heparan sulfate and dermatan sulfate from MPS I fibroblasts
and measured by electrospray tandem mass spectrometry, has
also been shown to discriminate between patients with and
without CNS pathology.26 These studies require long-term fibroblast cultures and mass spectrometry-based GAG assays.
Kingma et al27 developed an algorithm to predict clinical severity in MPS I based on genotyping and an optimized IDUA
assay, however, this assay is not routinely available. In a preliminary proteomic study, the lysosomal protein b-galactosidase
was elevated 3.6- to 5.7-fold in severe but not attenuated MPS
I,28 and 1 study has reported that serum heparin-cofactor IIthrombin complex levels can differentiate patients with severe
MPS I from patients with attenuated MPS I.29 Neither of these
studies evaluated the utility of these biomarkers in the neonate
or early infant, and, thus, their utility for use in NBS is limited.
Heterogeneity of IDUA Variants
Over 200 IDUA pathogenic variants have been identified.
Because MPS I is an autosomal recessive disorder, both pathogenic alleles are required to be identified to consider using genotype to predict phenotype. An analysis of pathogenic IDUA
variants in patients with MPS I has shown clear genotypephenotype correlations.30 Homozygosity or compound heterozygosity for common nonsense mutations (eg, p.W402X and
p.Q70X) predominated among patients with severe disease,

Table II. Challenges in predicting disease severity following positive NBS for MPS I
• No biochemical criteria reliably distinguish MPS I subtypes
• Many signs and symptoms that establish an MPS I diagnosis in older patients do not differentiate between attenuated and severe phenotypes, or are not present in
newborns
• In the absence of 2 pathogenic IDUA variants previously reported to be associated with defined disease severity, genotype/phenotype correlation is complicated by
the existence of private (reported only in single individuals with MPS I) missense mutations that can not be used to predict the phenotype
• IDUA enzyme analysis is complicated by pseudo-deficiency because of:
• Benign variants
• Reduced in vitro enzyme activity in clinically unaffected individuals
• Prevalence in African American population
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whereas patients with attenuated disease have at least 1 allele
that contains a missense or a splice site variant. Although 62%
of patient genotypes included at least 1 nonsense allele, all patients with 2 nonsense alleles, whether homozygous or compound heterozygous, had severe disease. However, not all
patients with severe disease had nonsense mutations.
Up to 70% of pathogenic variants are recurrent and, thus,
may be helpful in phenotype prediction. Although genotypephenotype correlations have been established with some
common variants, there are individuals and families with unique
missense variants that cannot be used to predict the clinical
phenotype.30-32
IDUA Pseudodeficiency
The presence of IDUA pseudodeficiency alleles (benign variants) complicates NBS screening for MPS I. Pseudodeficiency
is decreased IDUA enzyme activity when measured using
current artificial substrates with no evidence of altered GAG
metabolism.33-35 IDUA pseudodeficiency alleles can result in
decreased enzyme activity when found in the homozygous
state or in the compound heterozygous state with another
pseudodeficiency allele, a pathogenic variant, or a variant of
unknown significance. The Missouri NBS program reported
that of 46 infants with a positive NBS screen, 26 had leukocyte IDUA enzyme activity below normal levels but above levels
identified in patients with confirmed severe MPS I.36 Followup testing showed that uGAG levels in these infants were not
indicative of severe MPS I, and no patient was homozygous
or compound heterozygous for previously reported pathogenic variants. Four purported pseudodeficiency missense IDUA
alleles were identified (p.A79T, p.H82Q, p.D223N, and p.V322E)
of which p.A79T was prevalent in the African American
population.36 The common finding of pseudodeficiency in individuals detected by NBS complicates the interpretation of
confirmatory results, however, this is resolved in most cases
by DNA sequencing, which is now considered standard-ofcare when the diagnosis of MPS I is being considered.

Methods
An expert group of North American physicians, clinician scientists, and genetic counselors with experience in MPS I diagnosis, treatment, and management, as well as NBS, convened
to review state-of-the-art practices for diagnosis of infants with
MPS I identified through NBS programs. The expert group
invited to this discussion were defined by virtue of their active
participation in the development of diagnostics, clinical trials
and/or ongoing clinical evaluation, management of patients
with MPS, and participation in NBS programs. Current practice and evidence from both published information and personal experience was reviewed at a meeting in Salt Lake City
in March of 2015. Literature review was performed by searching PUBMED with key words: Mucopolysaccharidosis I, Hurler
syndrome, Hurler-Scheie syndrome, Scheie syndrome, NBS,
and lysosomal disorders; the bibliography was provided to
attendees before the meeting date. The objective of this review
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was to develop an algorithm for addressing patient follow-up
testing and monitoring given the wide clinical spectrum of MPS
I and the different therapeutic recommendations based on
disease subtype. Preliminary information on the algorithm developed was presented at the 2015 American Academy of Pediatrics Meeting.37
Evaluation, Diagnosis, and Management of
Patients Following Positive MPS I NBS
Currently, NBS programs for MPS I begin with analysis of IDUA
activity measured directly from the DBS. Available screening
assays include fluorometric,15,18 digital microfluidics,15 and
tandem mass spectrometry-based analyses.38-41 MPS I screening may be included in multiplex assays that include screens
for multiple lysosomal storage disorders in a single DBS
sample.40 If IDUA levels are below established cut-off values,
the process outlined in the algorithm in the Figure is proposed to confirm and delineate disease severity, and guide appropriate follow-up and treatment. The main concept underlying
this algorithm is the critical importance of precisely defining
the phenotype of the patient with particular emphasis on ensuring that patients with Hurler syndrome be identified and
directed to transplantation programs. The approaches used for
enzyme analysis from the NBS card uses artificial substrates
and are similar to the methodology that is used for the
diagnostic assay albeit with a much smaller sample volume.
Because of the latter consideration, a repeat assay using a fresh
blood sample is required after a positive NBS. The issue of
pseudodeficiency relates to the use of the artificial substrates
that are used to measure iduronidase enzyme activity. Both the
NBS assays and the diagnostic assay use these artificial substrates and, thus, are not able to distinguish pseudodeficiency
from true deficiency. The frequency of pseudodeficiency will
be different in different populations; data to date suggests that
the frequency is highest within the African American population. At this time, there does not appear to be straightforward means using the initial NBS card to definitively and
accurately exclude a diagnosis of MPS I after the positive NBS
result. Nevertheless, the seriousness of MPS I and the critical
need for early treatment initiation particularly for individuals
with Hurler syndrome necessitates the steps that follow.
Confirmatory IDUA enzyme analysis (from fresh blood leukocytes, serum, or plasma) should be performed for all DBSpositive newborn samples, ideally arranged by a geneticist/
metabolic disease team. A normal level of enzyme activity in
the confirmatory assay is indicative of a false positive DBS assay
thus excluding a diagnosis of MPS I. Following a positive
confirmatory enzyme assay, all patients should be urgently assessed by a genetic/metabolic disease specialist for further clinical, molecular, and biochemical assessments. Because the
turnaround time for the confirmatory enzyme analysis would
be approximately 1 week and, if positive, the subsequent step
of IDUA gene sequencing would have an approximate 3 weeks
turnaround time, it is anticipated that screening programs
would likely obtain both samples at the initial time of patient
recall and not proceed to IDUA gene sequencing until IDUA
deficiency is confirmed. It is anticipated that advances in se-
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Figure. Proposed decision making algorithm for positive MPS I newborn screen. VUS, variant of unknown significance (ie, nonrecurrent missense variant).

quencing technologies could result in a more rapid turnaround
for this step. Because of the complex nature of the discussion, the initial patient recall should be communicated to the
family and organized by a genetics/metabolic team that is well
versed in this condition. This would ensure appropriate and
supportive discussions take place as well as provide an opportunity for the care team to determine whether more rapid
clinical assessment of the newborn is required.
To accurately determine the appropriate management for
each patient, molecular, biochemical, and clinical assessments must be integrated into the decision-making process.
IDUA gene sequencing, biochemical assessment, and a comprehensive clinical evaluation (Tables I and III) should be performed following confirmation of low/deficient IDUA enzyme
activity. Quantitative uGAG determination using dye-binding
methodology is currently used by most laboratories. It is noteworthy that quantitative uGAG excretion in young infants can
be difficult to interpret. Although uGAG analysis has proven
to be useful as an initial screen in symptomatic older indi366

viduals, uGAG levels in newborns can be elevated relative to
older infants and normative data for infants under the age of
1 month have not been established in most laboratories. At this
time, other blood or urine glycosaminoglycan based quantitative methodologies24 have not been adequately evaluated in
the newborn period; as this data becomes available their potential role in NBS will emerge.
The patient’s genotype is an important component in
decision-making and should be interpreted in context with clinical and biochemical assessments.30 If the IDUA genotype analysis identifies 2 pathogenic alleles known to be or likely to be
associated with severe disease in the presence of elevated uGAG
levels (group 1 in algorithm), then the patient should be immediately referred for HSCT assessment with consideration
of peritransplant ERT because outcomes following HSCT for
severe MPS I are closely related to disease burden and, thus,
age at transplantation.5,48 Early diagnosis and treatment is highly
correlated with improved cognitive, language, and behavioral
outcomes,48 and may also impact long-term musculoskeletal
Clarke et al
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Table III. Clinical evaluations/observations helpful for MPS I disease severity assessment
Assessments
Musculoskeletal including radiologic
assessment to identify early signs of
dysostosis multiplex
Cardiac including echocardiogram for signs
of heart valve thickening and ECG

Neurologic
Neurocognitive

Brain and spine imaging

Hydrocephalus
Ophthalmological including visual acuity,
retinal exam and corneal exam
Respiratory including airway and nasal
congestion and lung function tests

Observation for facial dysmorphisms

Gastrointestinal including spleen volume,
liver volume and observation for hernia
Audiometry

Severe MPS I
Severity of the dysostosis tends to correlate with disease severity;
mild dysostosis, particularly of the hips, ribs, and vertebrae can be
detected on radiographs at birth. Gibbus deformity an early sign of
severe disease
Early signs of valvular disease are suggestive of severe MPS I
disease; cardiac involvement by echocardiography is observed
much earlier than clinical symptoms; mitral valvular disease most
common,44 rare cases of early endocardiofibroelastosis
Early psychomotor development may be normal; developmental
delay is usually obvious by age 18 mo; language delays22

Signal alterations, enlarged PVS, and ventriculomegaly are
consistent findings, although incidence in the early months of life
is unknown46
Communicating high-pressure hydrocephalus is common; increase
in intracranial pressure can contribute to rapid cognitive decline22
Early detectable corneal involvement is suggestive of more severe
MPS I disease and may be observable by 6-7 wk of age
Frequent upper respiratory-tract infections common before age 1 y;
chronic recurrent rhinitis and persistent copious nasal discharge
without obvious infection are also common; sleep apnea
common22
Coarsening of the facial features, caused by storage of GAGs in the
soft tissues of the orofacial region and facial bone dysostosis,
becomes apparent within the first 2 y22
Inguinal or umbilical hernias are common before age 1 y in severe
MPS I; hepatosplenomegaly is common22
Hearing loss is common in severe MPS I and correlates with severity
of somatic disease22

Attenuated MPS I
Later onset of skeletal abnormalities22,42,43

Cardiac involvement detected at later age than
in severe MPS I45

In attenuated MPS I intellect may be normal or
nearly normal. If intellectual abilities decline,
the course is more protracted than in
individuals with severe disease.
Signal alterations, enlarged PVS, and
ventriculomegaly and spinal stenosis are
frequent findings, atrophy is less frequent42
Lower frequency early in attenuated MPS I, but
may have insidious onset22
Onset of corneal clouding at later age (median
age 9.1 y) than in severe MPS I42
Rhinorrhea and sleep apnea are common;22
recurrent ear nose and throat symptoms46

Coarseness of facial features less obvious than
in severe MPS I42,47
Hernia present in 65% of patients with
attenuated MPS I, with median onset 3 y;42
hepatosplenomegaly variable22
Moderate to severe hearing loss may develop22

ECG, electrocardiography; PVS, perivascular spaces.

disease.49 Although the current recommendation for a patient
diagnosed with Hurler syndrome is to offer early transplantation, there are no data available that precisely delineates the
most favorable time to initiate transplantation. Thus, the exact
timing of transplantation after a NBS based diagnosis of severe
MPS I will require the transplant center to take into account
transplant risks as well as risks of disease progression. The collection of outcome data for patients with MPS I diagnosed by
NBS will be critical in providing future insights into this
important question. If attenuated disease is predicted by the
variants identified (group 2 in algorithm), then the patient
should be considered for initiation of ERT. Early initiation of
ERT is believed to improve clinical outcomes, possibly by preventing irreversible changes that result from GAG accumulation and secondary pathogenic cascade activation.50,51 This
concept is supported by the observations that lysosomal GAG
storage in MPS occurs prenatally,52,53 outcomes are improved
with very early treatment in animal models,54,55 and early vs
later treatment improves outcomes in sibling case studies.47,56,57
The proposed algorithm (Figure) uses IDUA sequencing as
a critical component in decision-making. The 2 relatively
straightforward situations where genotype and biochemical
profiles are predictive of severe (group 1) or attenuated disease
(group 2) should lead to prompt treatment initiation. Conversely, there are situations that necessitate clinical and biochemical monitoring in the first 6 months of life to ensure
appropriate treatment consideration. In cases where there is

not clear genotype-phenotype correlation and disease severity
cannot be predicted because of the presence of variants of
unknown significance (group 3 of the algorithm), the physical examinations, clinical evaluations, and biochemical
assessments may help in predicting the disease course. A
detailed physical examination should include assessment
for facial dysmorphisms, corneal clouding, joint range of
motion, hernias (both inguinal and umbilical), murmurs, liver
and spleen enlargement, and scoliosis/kyphosis. The clinical
assessments (Table III) should include skeletal radiographs,
echocardiography, neurocognitive evaluation, ophthalmologic examination, and consideration of brain magnetic resonance imaging (MRI). These evaluations can assist in the
identification of patients with severe MPS I because findings
of dysostosis multiplex, gibbus deformity, and significant detectable corneal and cardiac valve involvement, in addition to
respiratory findings in a newborn infant of 6-7 weeks of age
are consistent with a severe disease phenotype. Although the
sensitivity of brain MRI to distinguish disease severity early
in natural history of disease is uncertain, brain MRI may be
helpful in the early classification of patients as early white
matter changes would be indicative of Hurler syndrome.
Because brain MRI requires sedation, this should be considered when indicated by other findings of the full clinical assessment. Early neurosensory hearing loss as opposed to
conductive hearing loss may indicate possible Hurler syndrome.
In cases where symptoms are not apparent in early infancy or
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the symptoms do not clearly indicate severe disease, frequent
follow-up is necessary to more confidently predict disease severity and, thus, the most appropriate treatment course.
In cases where the disease severity cannot be predicted (group
3), clinical and biochemical follow-up is important in establishing the appropriate treatment plan. Assessments should be
conducted at 3 and 6 months of age at a minimum, and for
longer duration depending on clinical need. Parental and sibling
testing may provide insights into the potential phenotype associated with these alleles. For example, if an older sibling had
identical findings, this would provide insight into disease
severity. Most patients with severe MPS I will show signs of
clinical disease by 6 months of age. There is concern that
commencement of ERT early in group 3 patients could potentially mask the clinical signs that would lead to distinction between whether a patient would be designated as Hurler
or attenuated. For the most part, this will not be difficult for
families to accept provided a clear rationale is provided to them.
The reality is that group 3 should represent a small group of
patients who should have minimal symptoms of disease. If
at this young age the patient had significant disease symptoms, the clinical team would likely correctly classify the patient
as Hurler and, thus, process accordingly. For patients who
cannot be conclusively classified with severe MPS I, or when
evaluations indicate attenuated disease, ERT should be started
at least by 6 months of age, with the caveat that the characteristic features that may lead to classifying the patient as
Hurler syndrome may be masked if ERT is initiated too early,
thus, resulting in delay in HSCT initiation.
If a patient has low confirmatory enzyme levels with normal
uGAG and normal clinical assessment in the presence of 1 or
2 pseudodeficiency genes, the NBS is assumed to be a false positive (group 4 of the algorithm). Follow-up in 6 months to a
year may be considered to confirm that the decreased enzyme
activity is benign as well as to alleviate parental concerns. Confirmation of a single pathogenic mutation would be indicative of carrier status, however, and should prompt appropriate
genetic counseling of other family members.

Discussion
The algorithm developed by this working group should provide
guidance for interpreting NBS results for MPS I and a framework for the management of infants with this disease who are
diagnosed in the newborn period. To assess the effectiveness
of NBS for MPS I as well as to address practical issues related
to which clinical features at what age and which biomarkers
are most helpful in providing clinical delineation of patients,
a coordinated effort for data collection as well as the potential of establishment of a sample repository for biomarker
evaluation and discovery should be considered. The group
acknowledges that they represent a small number of individuals who would be considered as MPS experts but feel that this
guidance document will aid in providing the background necessary for physicians to understand the complexity of NBS for
MPS I. Although the initial confirmation of a positive MPS I
newborn screen can be initiated by a wide range of providers,
368
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it is recommended that geneticists/metabolic disease specialists
be notified of the positive screen and be closely involved in the
interpretation and organization of the confirmatory analysis.
This will ensure that families receive accurate and timely information regarding this complex disorder. In addition to direct
management of the identified case, genetic counseling should
be provided to all families for ongoing support related to NBS
applications, disease education, reproductive counseling for the
parents, identification of at-risk older siblings, developing a
testing plan for subsequent siblings, and discussion about carrier
testing for at risk family members. ■
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